Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)

Prior treatment

• Surgery for obesity in the last 6 months.
• Previous participation in Maridebart cafraglutide trial.
• Alcohol or drug abuse.

Other illness

• Type 1/Type 2 diabetes mellitus (DM).
• Obesity induced by other endocrine disorder (ex: Cushing's syndrome).
• History of malignancy in the last 5 tears except for nonmelanoma skin cancers, cervical, or breast ductal carcinoma in situ.
• Uncontrolled thyroid disease.
• Heart attack within 3 months.
• History of ischemic optic neuropathy.
• Positive HIV or certain positive Hepatitis B or hepatitis C.

Other

• Acute \& chronic pancreatitis within 1 year.
• Gastroparesis or gastric outlet obstruction.
• Current use of compounded weekly GLP-1RA.
• Pregnancy, breastfeeding, or planning to breastfeed.

• 18 to 70 years of age.
• Body Mass Index (BMI) ≥ 25 at screening.
• BMI ≥ 23 for Asian participants at screening.
• Stable body weight (approximately 5% or less gain or loss) during the 4-week run-in period, unless the study doctor determines otherwise.
• Stable dose of weekly GLP-1RA.
• Stable gastrointestinal (GI) tolerability.
• Contraception for females.
• Stable for 3 months if obstructive sleep apnea (OSA), hypertension, hyperlipidemia, and/or hypothyroidism.
• Willingness to follow trial procedures for the duration of the trial.